Biotek-snakken — November 2020
-
Har fulgt Scandion Oncology tæt siden 2019 og mener de har en god og solid teknologi. Har talt med både CEO og CSO og har tillid til ledelsen og at de med emissionen, nok skal få maksimeret potentialet i SCO-101 og pipelinen. Det var en streg i regningen at de udskød data read out for Ph II part 1 i kolorektal cancer til Q2 21. Så det kræver nok noget tålmodighed og is i maven at være i Scandion Oncology det næste stykke tid...
-
-
Interessant med ALX, kan se de har vist spændende resultater. https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-announces-new-data-aspen-01-phase-1b-study-alx148
-
Stadig intet nyt omkring ZW49, MTD er endnu ikke nået. Omkring partner på zanidatamab: "Confident to say that we know what we want, who we
want and when we want". -
"One or more partner programs going into the clinic in 2021"
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind